Elsevier Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Chung
    Chung
  3. Hassoun
    Hassoun
  4. Korde
    Korde
  5. Landau
    Landau
  6. Lesokhin
    Lesokhin
  7. Mailankody
    Mailankody
  8. Shah
    Shah
  9. Shah
    Shah
  10. Tan
    Tan

Groups

  1. Biostatistics Service (28)
  2. Center for Hematologic Malignancies (28)
  3. Department of Medicine (28)
  4. Epidemiology and Biostatistics (28)
  5. Hematologic Malignancies, Division of (28)
  6. Survivorship Research (23)
  7. Bone Marrow Transplant (21)
  8. Hematologic Malignancies Research (21)
  9. Myeloma (21)
  10. CTCR Scholars (19)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Biostatistics Service"
  3. "Clinical Lymphoma, Myeloma and Leukemia"
Formats
  1. Meeting Abstract (28)
Groups
  1. Biostatistics Service (28)
  2. Center for Hematologic Malignancies (28)
  3. Department of Medicine (28)
  4. Epidemiology and Biostatistics (28)
  5. Hematologic Malignancies, Division of (28)
  6. Survivorship Research (23)

More Groups

People
  1. Sergio Giralt (21)
  2. Alexander Lesokhin (20)
  3. David Chung (20)
  4. Hani Hassoun (20)
  5. Heather Landau (20)
  6. Neha Korde (20)

More People

Years
  1. 2023 (12)
  2. 2022 (6)
  3. 2021 (2)
  4. 2019 (2)
  5. 2017 (4)
  6. 2014 (2)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (28)

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save